LLY Healthcare
Eli Lilly & Co.
| P/E Trailing | 42.55 |
| P/E Forward | 26.97 |
| PEG Ratio | 1.56 |
| Market Cap | $1.07T |
| Price Target | $1222.62 (+1.9%) |
| D/E Ratio | 139.02 |
| Current Ratio | 1.50 |
| Cash | $5.28B |
| Total Debt | $43.37B |
| Net Cash | $-38.09B |
| Gross Margin | 82.83% |
| Operating Margin | 49.39% |
| Net Margin | 34.99% |
| ROE | 107.46% |
| FCF | $9.16B |
| GF Score | -- |
| Altman Z-Score | -- |
| Piotroski F-Score | -- |
| Div. Yield | 58.00% |
| Analyst Rating | buy |
HOLD: High leverage - monitor debt levels. Strong profitability with 107.5% ROE. 58.00% dividend yield provides income.
The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.
By Deena Beasley June 30 (Reuters) - The chair of the U.S.
Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.
Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.
Eli Lilly transferred mainland China commercialization rights for Verzenio to Innovent Biologics.
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China …
The abbreviated week in the market could set the tone for the back half of 2026.
Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.
Innovent will take over importing, marketing, and distributing Verzenios in mainland China as generic competition looms